New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05264259

Acronym

AcMBK

Enrollment

100

Registered

2022-03-03

Start date

2022-09-05

Completion date

2025-12-01

Last updated

2025-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BK Virus Infection

Brief summary

BK virus (BKV) infection has a major negative impact on transplant recipients. No BKV-specific antiviral therapy is available, so there is an urgent need to develop new anti-BKV preventive and therapeutic strategies.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* BK positive * adult * ok to participed to research

Exclusion criteria

* under guardianship * under curatorship * opposed to research * deprived of liberty

Design outcomes

Primary

Measure	Time frame	Description
Ability of the isolated monoclonal antibodies to neutralize all 3 BKV genotypes	5 years	The neutralization titer will be defined as the dilution of the sample that produced 50% inhibition of pseudovirion infectivity (IC50)

Countries

France

Contacts

Primary ContactAnne-Sophie U GEY

anne-sophie.gey@chru-strasbourg.fr+33 388116684

Outcome results